| Abstrakt: |
Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines: nonadjuvanted vaccine or vaccine adjuvanted with alum - given concomitantly with influenza vaccine to high-risk elderly individuals. Even cost-effective analyses of RSV prevention increasingly find that the healthcare resource utilization costs following RSV are an important contributor to the overall burden of RSV disease [[50]]. This analysis showed that RSV-specific antibody appeared to protect mice from RSV disease but not cows from bovine RSV. Keywords: hospitalization; epidemiology; RSV prevention; vaccines; costs EN hospitalization epidemiology RSV prevention vaccines costs S1 S9 9 08/18/22 20220802 NES 220802 Soon after the discovery that respiratory syncytial virus (RSV) was the major cause of bronchiolitis in infants, in 1956 [[1]], vaccines were developed to try and prevent both infection and severe disease caused by the virus, but such early preventive efforts failed [[2]]. [Extracted from the article] |
